An investor in NYSE:AGN shares filed a lawsuit against Allergan plc over alleged Securities Laws violations in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Allergan plc (NYSE:AGN) have certain options and for certain investors are short and strict deadlines running. Deadline: January 3, 2017. NYSE:AGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The plaintiff alleges on behalf of purchasers of Allergan plc (NYSE:AGN) common shares between February 25, 2014 and November 3, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 25, 2014 and November 3, 2016, the Defendants made certain false and/or misleading statements and/or failed to disclose that Allergan and Actavis were allegedly engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice, that the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Allergan and Actavis by the end of 2016 for suspected price collusion. that in turn, Allergan and Actavis lacked effective internal controls, and that as a result, Allergan plc’s and Actavis plc’s public statements were materially false and misleading at all relevant times.
According to news reports United States prosecutors may file criminal charges against Allergan plc and others by the end of 2016 for suspected price collusion. It was reported that the, “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies and about two dozen drugs, according to people familiar with the matter. The grand jury probe is examining whether some execudtives agreed with one another to raise prices, and the first charges could emerge by the end of the year, they said.” The companies identified as targets or relevant parties in the United States investigation include Mylan NV, Teva Pharmaceutical Industries Ltd, Allergan Plc, Lannett Co., Impax Laboratories Inc., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo International Plc and Taro Pharmaceutical Industries Ltd.
Allergan plc Ordinary Shares (NYSE:AGN) declined on November 3, 2016 to as low as $186.34 per share.
Those who purchased NYSE:AGN shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com